Ester Sklarsky joins Sound Bioventures

Read about Ester Sklarsky and how her curiosity for life-science and innovation shaped a career in VC, permitting her to pursue the therapeutics of tomorrow and make a difference for patients.

Today we welcome Ester Sklarsky to the Sound Bioventures investment team as an Associate. Ester will manage our dealflow, identify new investment opportunities and conduct scientific and commercial due diligence.

Ester joins us from Industrifonden where she made life science venture capital investments as an analyst as well as an associate. Ester also has prior experience as a management consultant at Sirona Health Solutions, where she worked with key stakeholders in the Swedish public healthcare sector, as well as as an equity analyst at the bank DNB, where she focused on the Biotech sector.

Ester holds a bachelor’s degree in Biomedicine from the Karolinska Institute and a master’s degree in Bioentrepreneurship, also fromthe  Karolinska Institute.

Ester will be based at the Stockholm, SE, office.

Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases

Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Developed for Once Daily Oral Dosing to Address Autoimmune Diseases by Providing Immunomodulation without Immunosuppression Cambridge, Mass., June 1, 2023 – Artax ...